Exact Sciences (EXAS) PT Raised to $85 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Exact Sciences (EXAS) PT Raised to $82 at BTIG
September 16, 2024 3:09 PM EDTBTIG analyst Mark Massaro raised the price target on Exact Sciences (NASDAQ: EXAS) to $82.00 (from $70.00) while maintaining a Buy rating.
The analyst comments "Shares of EXAS are up ~5% today (and +20% in the last few days) following EXAS' blood-based CRC test readout from a ~3,000 patient, partial case control study read out during the European Society of Medical Oncology (ESMO)... More
Citi Reiterates Buy Rating on Exact Sciences (EXAS)
September 16, 2024 8:26 AM EDTCiti analyst Patrick Donnelly reiterated a Buy rating and $80.00 price target on Exact Sciences (NASDAQ: EXAS).
The analyst comments "This morning, EXAS released initial data on their blood-based CRC test at ESMO. The test showed overall CRC sensitivity of 88.3%, specificity of 90.1%, and AA... More
